Page 63 - Read Online

Page 12 of 16 Zhang et al. Neuroimmunol Neuroinflammation 2019;6:8 I http://dx.doi.org/10.20517/2347-8659.2019.06

48. Martinelli V, Roca MA, Annovazzi P, Pulizzi A, Rodegher M, et al. A short-term randomized MRI study of high dose oral vs intravenous
methylprednisolone in MS. Neurology 2009;73:1842-8.
49. Burton JM, O’Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Cochrane Database Syst Rev 2009;8:CD006921.
50. Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, et al. A randomized clinical trial of oral versus intravenous
methylprednisolone for relapse of MS. Mult Scler 2014;20:717-25.
51. Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, et al. Oral versus intravenous high-dose methylprenisolone for treatment
of relapses in patients with multiple sclerosis (COPOUSEP): a randomized, controlled, double-blind, non-inferiority trial. Lancet
2015;386:974-81.
52. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, et al. EFNS guideline on treatment of multiple sclerosis relapses: report
of an EFNS task force on treatment of multiple sclerosis relapses. Eur J of Neurol 2005;12:939-46.
53. Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, et al. Oral prednisone taper following intravenous steroids fails to improve disability
or recovery from relapses in multiple sclerosis. Eur J Neurol 2008;15:677-80.
54. Levic Z, Micic D, Nikolic J, Stojisavljević N, Sokić D, et al. Short-term high dose steroid therapy does not affect the hypothalamic-
pituitary-adrenal axis in relapsing multiple sclerosis patients. J Endocrinol Invest 1996;19:30-4.
55. Wenning GK, Wietholter H, Schnauder G, Muller PH, Kanduth S, et al. Recovery of the hypothalamic-pituitary-adrenal axis from
suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. Acta Neurol Scand 1994;89:270-3.
56. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a
retrospective analysis. Mult Scler 2007;13:968-74.
57. Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, et al. Clinical course, therapeutic responses and outcomes in relapsing
MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018;89:127-37.
58. Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K; Brazilian Committee for Treatment and Research in Multiple Sclerosis. Treatment
of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 2012;70:59-66.
59. Palace J, Leite MI, Jacob A. A practical guide to the treatment of neuromyelitis optica.Pract Neurol 2012;12:209-14.
60. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome).
Neurology 1999;53:1107-14.
61. Bichuetti DB, Oliveira EM, Souza NA, Tintoré M, Gabbai AA. Patients with neuromyelitis optica have a more severe disease than
patients with relapsing remitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arq Neuropsiquiatr
2013;71:275-9.
62. Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, et al. Efficacy of intravenous methylprednisolone pulse therapy in
patients with multiple sclerosis and neuromyelitis optica. Mult Scler 2016;22:1337-48.
63. Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010;12:244-55.
64. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher 2002;17:207-11.
65. McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A. Immunomodulatory therapies in neurologic critical care. Neurocrit Care
2010;12:132-43.
66. Lipphardt M, Mühlhausen J, Kitze B, Heigl F, Mauch E, et al. Immunoadsorption or plasma exchange in steroid-refractory multiple
sclerosis and neuromyelitis optica. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jca.21686. [Last accessed on 23 Apr
2019]
67. Correia I, Ribeiro JJ, Isidoro L, Batista S, Nunes C, et al. Plasma exchange in severe acute relapses of multiple sclerosis - results from a
portuguese cohort. Mult Scler Relat Disord 2018;19:148-52.
68. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207
therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018;5:e504.
69. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients
with neuromyelitis optica. Mult Scler 2007;13:128-32.
70. Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis
optica. Arch Ophthalmol 2012;130:858-62.
71. Bonnan M, Valentino R, Debeugny S, Merle H, Fergé JL, et al. Short delay to initiate plasma exchange is the strongest predictor of
outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89:346-51.
72. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment
courses. Ann Neurol 2016;79:206-16.
73. Schwab, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol
2013;13:176-89.
74. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of
neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20:501-4.
75. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M, et al. IV immunoglobulins as add-on treatment to methylprednisolone for
acute relapses in MS. Neurology 2004;63:2028-33.
76. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, et al. A randomized, double-blind, place-controlled pilot study of IV immune
globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004;10:89-91.
77. Olyaeemanesh A, Rahmani M, Goudarzi R, Rahimdel A. Safety and effectiveness assessment of intravenous immunoglobulin in the
treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Med J Islam Repub Iran 2016;30:336.
78. Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 2013;28:65-72.
79. Viswanathan S, Wong AH, Quek AM, Yuki N. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J
Neuroimmunol 2015;282:92-6.